EpiBiologics
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
$107MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
Pitching Aulis Capital? Send the deck from a free RoundOS data room and see which pages they read.